Clinical trials: Claudin18.2 Positive Advanced Solid Tumors
Advanced Solid Tumors
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory…
- Trial name
- NCT07460375
- Testing
- LCB02A
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 191 people
- Sponsor
- LigaChem Biosciences, Inc.
Gastric Cancer
Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial
The goal of this clinical trial is to assessing the safety and tolerability of XKDCT086 cells against recurrent or refractory solid tumors with Claudin18.2 positivity.This experiment proposes to enroll 9-18 patients, the…
- Trial name
- NCT05952375
- Testing
- Chimeric antigen receptor T cell preparation targeting Claudin18.2
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Advanced Solid Tumors
A Study of QLS31905 in Patients With Advanced Solid Tumors
This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.
- Trial name
- NCT05278832
- Testing
- QLS31905
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor
RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors
IP: RD07 cell injection; Target disease：solid tumor; Protocol design： Single arm, open label, dose increasing design. The experiment was divided into two stages: dose increasing stage and dose extension stage.
- Trial name
- NCT05284968
- Testing
- Cell injection
- Volunteers
- 36 people
- Sponsor
- Peking University
Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
A IIT Study of 177Lu-DOTA-SNA040
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced…
- Conditions
- Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)
- Trial name
- NCT07595237
- Testing
- 177Lu-DOTA-SNA040
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
Claudin18.2 Positive Advanced Solid Tumors
CAR-T for Claudin18.2 Positive Solid Tumors
The purpose of this clinical trial is to learn if autologous claudin18.2-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat claudin18.2 positive solid tumors in adults.
- Trial name
- NCT07266311
- Testing
- claudin18.2 CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chengdu Ucello Biotechnology Co., Ltd.
Claudin18.2 Positive Advanced Solid Tumors
Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)
A single-center, single-arm, dose-escalation exploratory clinical trial of the safety, efficacy, and pharmacokinetics of XKDCT225 cell injection in Claudin18.2-positive advanced solid tumors
- Trial name
- NCT06782425
- Testing
- XKDCT225
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.